TARSUS PHARMACEUTICALS INC (TARS) Stock News
NASDAQ:TARS - Nasdaq - US87650L1035 - Common Stock - Currency: USD
TARS Latest News, Press Relases and Analysis
Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements
Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, during the first full year of...
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00...
Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in...
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tarsus Pharmaceuticals (NASDAQ:TARS) just reported results for the second quart...
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved...
Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run
The company sells one drug to treat a condition that causes dry, red and itchy eyes. But rosacea and Lyme disease could be next.
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer...
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif.,...
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
Dr. Yeu transitions from her role as Chief Medical Advisor and Board Member to lead the Company’s newly created Medical Organization...
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
Dr. Yeu transitions from her role as Chief Medical Advisor and Board Member to lead the Company’s newly created Medical Organization
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients’ eyelids Demodex blepharitis...
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
TARS stock results show that Tarsus Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven...